Memorial Sloan Kettering

Site:	Memorial Sloan Kettering	Go to their website
Address:	1275 York Ave
City:	New York
State:	NY
Zip:	10065
Country:	USA

41 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	Completed	Closed	BIIB021 (CNF2024)	NCT00618319
1	A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Binimetinib + Pexidartinib	NCT03158103
1	Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + MEK162	NCT01363232
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
2	Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Ongoing, but not recruiting	Closed	Cixutumumab + Temsirolimus	NCT01016015
1	Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic	Completed	Closed	Dasatinib + Ipilimumab	NCT01643278
1/2	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
1	Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery	Completed	Closed	Doxorubicin + Flavopiridol	NCT00098579
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Completed	Closed	GDC-0449 + RO4929097	NCT01154452
1	Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody	Active, not recruiting	Closed	HuF9-G4	NCT02216409
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
	Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib	NCT00580281
1/2	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Ongoing, but not recruiting	Active	Imatinib + BGJ398	NCT02257541
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
1b/2	MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Imatinib + MEK162	NCT01991379
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Active	INBRX-109 + Temozolomide	NCT03715933

Memorial Sloan Kettering

41 trials at this site

Page 1 of 3 | Next | Last